PISTORESI MARIA CRISTINA
Congresos y reuniones científicas
Título:
Infection of murine cell lines with retrovirus HTLV-1 through cell-free virus concentrates
Autor/es:
BARBAS, MG; BALANGERO, M; MALETTO, B; PISTORESI-PALENCIA, MC; LUJAN, H; MORON, G; GALLEGOS, S
Lugar:
Córdoba. Argentina
Reunión:
Congreso; VII Congreso Latinoamericano de Inmunología.; 2005
Institución organizadora:
Asociación Latinoamericana de Inmunología
Resumen:

INFECTION OF MURINE CELL LINES WITH RETROVIRUS HTLV-1 THROUGH CELL-FREE VIRUS CONCENTRATES

 Barbás, María Gabriela1, Balangero Marcos1, Belkys Maletto2, Pistoresi M.Cristina2, Luján Hugo3, Gabriel Morón2 and Gallego Sandra1.

 1 Instituto de Virología, FCM, Univ.Nac. de Córdoba.

2 CIBICI-CONICET, UNC.

3 INIMEC-CONICET, Córdoba

The main challenges in the field of the retrovirus HTLV-1 are the development of an effective vaccine for preventing HTLV-1 infection as well as the development of therapeutic vaccines for the treatment of ill individuals. The establishment of in vitro and in vivo models of HTLV-1 infection, is crucial to acomplish the development of an anti-HTLV-1 vaccine. We intend to develop and standardize new in vitro and in vivo systems for HTLV-1 infection.

We successfully infected a murine cell line (EL-4) with a cell-free virus concentrate, obtained from MT-2 (HTLV-1 persistently infected human T cell line) cell-culture supernatant. Infection of cells was corroborated by IFA using anti-HTLV-1 antibodies and detecting the provirus using Nested-PCR from 24 h to at least 5 days post-inoculation. The neutralization of infection was carried out using serial 10-fold dilutions of a polyclonal serum from an asymptomatic HTLV-1 infected subject. Total neutralization was obtained at 3 hours post-inoculation. Using this cell-free virus infected murine cell lines we will intend to standardize the conditions to infect mice with HTLV-1, in order to have an in vivo model to evaluate humoral and cellular immune response against different HTLV-1 peptides and to assess the protective capacity of the vaccine to be developed.